JP2018504094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504094A5 JP2018504094A5 JP2017529750A JP2017529750A JP2018504094A5 JP 2018504094 A5 JP2018504094 A5 JP 2018504094A5 JP 2017529750 A JP2017529750 A JP 2017529750A JP 2017529750 A JP2017529750 A JP 2017529750A JP 2018504094 A5 JP2018504094 A5 JP 2018504094A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- chain variable
- variable region
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 173
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 158
- 239000000427 antigen Substances 0.000 claims description 150
- 102000036639 antigens Human genes 0.000 claims description 150
- 108091007433 antigens Proteins 0.000 claims description 150
- 230000004048 modification Effects 0.000 claims description 112
- 238000012986 modification Methods 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 54
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 230000028993 immune response Effects 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 22
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 16
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 16
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 16
- 230000000139 costimulatory effect Effects 0.000 claims description 16
- 230000011664 signaling Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 201000000564 macroglobulinemia Diseases 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 108010083359 Antigen Receptors Proteins 0.000 claims description 2
- 102000006306 Antigen Receptors Human genes 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- -1 CD86 Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 230000036039 immunity Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022029515A JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A JP7864752B2 (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2026081108A JP2026126417A (ja) | 2014-12-05 | 2026-05-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088164P | 2014-12-05 | 2014-12-05 | |
| US62/088,164 | 2014-12-05 | ||
| PCT/US2015/064134 WO2016090337A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029515A Division JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504094A JP2018504094A (ja) | 2018-02-15 |
| JP2018504094A5 true JP2018504094A5 (enExample) | 2019-01-17 |
| JP7174522B2 JP7174522B2 (ja) | 2022-11-17 |
Family
ID=56092578
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529750A Active JP7174522B2 (ja) | 2014-12-05 | 2015-12-04 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2022029515A Withdrawn JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A Active JP7864752B2 (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2026081108A Pending JP2026126417A (ja) | 2014-12-05 | 2026-05-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029515A Withdrawn JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A Active JP7864752B2 (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2026081108A Pending JP2026126417A (ja) | 2014-12-05 | 2026-05-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11059891B2 (enExample) |
| EP (2) | EP3227436B1 (enExample) |
| JP (4) | JP7174522B2 (enExample) |
| KR (1) | KR20170108946A (enExample) |
| CN (2) | CN109072199B (enExample) |
| AU (2) | AU2015357543B2 (enExample) |
| BR (1) | BR112017011936A8 (enExample) |
| IL (2) | IL252655B (enExample) |
| MX (1) | MX395028B (enExample) |
| MY (1) | MY192062A (enExample) |
| NZ (1) | NZ732570A (enExample) |
| PH (1) | PH12017501041A1 (enExample) |
| SG (2) | SG10202008076RA (enExample) |
| WO (1) | WO2016090337A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| JP6974311B2 (ja) * | 2015-06-23 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | 新規ｐｄ−１免疫調節剤 |
| PH12018501177B1 (en) | 2015-12-04 | 2024-01-24 | Eureka Therapeutics Inc | Antibodies targeting fc receptor-like 5 and methods of use |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| US12065498B2 (en) | 2017-09-29 | 2024-08-20 | Cell Design Labs, Inc. | Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same |
| WO2019084538A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| CN118047873A (zh) | 2017-12-29 | 2024-05-17 | 圆祥生技股份有限公司 | 调节免疫检查点作为癌症治疗的单特异性蛋白质 |
| US12247060B2 (en) * | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3758735B1 (en) * | 2018-02-28 | 2023-12-13 | AP Biosciences, Inc. | Bifunctional proteins combining checkpoint blockade for targeted therapy |
| US12410234B2 (en) | 2018-04-26 | 2025-09-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for retrieving tumor-related antibodies and antigens |
| WO2019220109A1 (en) | 2018-05-15 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| SG11202102781UA (en) | 2018-09-27 | 2021-04-29 | Autolus Ltd | Chimeric antigen receptor |
| US12129305B2 (en) | 2018-10-25 | 2024-10-29 | The Medical College Of Wisconsin, Inc. | Targeting CLPTM1L for treatment and prevention of cancer |
| MX2021005048A (es) | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| CN114929738B (zh) * | 2019-08-07 | 2026-01-02 | 水肺治疗公司 | 抗nampt抗体及其用途 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US12642847B2 (en) | 2020-05-27 | 2026-06-02 | Vanderbilt University | Human monoclonal antibodies to Venezuelan equine encephalitis virus and uses therefor |
| CN113801228B (zh) * | 2020-06-17 | 2023-01-17 | 常州费洛斯药业科技有限公司 | 靶向cd38的单链抗体、全人源嵌合抗原受体、制备方法和应用 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| EP4355781A1 (en) * | 2021-06-18 | 2024-04-24 | Autolus Limited | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases |
| WO2023010122A2 (en) | 2021-07-29 | 2023-02-02 | Sonoma Biotherapeutics, Inc. | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
| WO2023200873A2 (en) * | 2022-04-12 | 2023-10-19 | Washington University | Chimeric antigen receptor compositions and methods of using the same |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| KR20250022800A (ko) | 2022-06-10 | 2025-02-17 | 우모자 바이오파마 인코포레이티드 | 조작된 줄기 세포 및 그의 용도 |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| KR20250048566A (ko) * | 2022-08-08 | 2025-04-09 | 일라이 릴리 앤드 캄파니 | 트랜스페린 수용체 결합 단백질 및 접합체 |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| US20260176651A1 (en) | 2022-11-04 | 2026-06-25 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US20260232729A1 (en) | 2023-02-03 | 2026-08-13 | C3S2 Gmbh | Methods for non-viral manufacturing of engineered immune cells |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250144234A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics Inc. | RNA for In vivo Transfection with Increased Expression |
| IL328711A (en) | 2023-12-13 | 2026-07-01 | Umoja Biopharma Inc | Myeloid cells derived from engineered induced stem cells and methods for differentiating and using them |
| IL328626A (en) | 2023-12-15 | 2026-07-01 | Capstan Therapeutics Inc | Humanized anti-CD8 antibodies and their uses |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
| WO2026123001A2 (en) | 2024-12-06 | 2026-06-11 | Umoja Biopharma, Inc. | Lineage-loci engineered cell therapy and related methods of producing and using same |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0721015B1 (en) | 1993-09-03 | 2004-10-27 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody that induces apoptosis |
| EP1232392B2 (de) | 1999-10-12 | 2014-04-02 | Oxoid (Ely) Limited | Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US7999077B2 (en) * | 2004-09-30 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IRTA2 antibodies and methods of use |
| EP1846449A4 (en) | 2005-01-12 | 2009-07-08 | Medarex Inc | IRTA-2 ANTIBODIES AND THEIR USE |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| PE20120877A1 (es) | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| MA33256B1 (fr) | 2009-04-01 | 2012-05-02 | Genentech Inc | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| CN113698497A (zh) * | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| PH12018501177B1 (en) * | 2015-12-04 | 2024-01-24 | Eureka Therapeutics Inc | Antibodies targeting fc receptor-like 5 and methods of use |
-
2015
- 2015-12-04 WO PCT/US2015/064134 patent/WO2016090337A1/en not_active Ceased
- 2015-12-04 AU AU2015357543A patent/AU2015357543B2/en active Active
- 2015-12-04 BR BR112017011936A patent/BR112017011936A8/pt not_active IP Right Cessation
- 2015-12-04 JP JP2017529750A patent/JP7174522B2/ja active Active
- 2015-12-04 CN CN201580075562.5A patent/CN109072199B/zh active Active
- 2015-12-04 MX MX2017007249A patent/MX395028B/es unknown
- 2015-12-04 CN CN202211233565.5A patent/CN116063565A/zh active Pending
- 2015-12-04 EP EP15864773.5A patent/EP3227436B1/en active Active
- 2015-12-04 MY MYPI2017000852A patent/MY192062A/en unknown
- 2015-12-04 SG SG10202008076RA patent/SG10202008076RA/en unknown
- 2015-12-04 KR KR1020177018388A patent/KR20170108946A/ko not_active Ceased
- 2015-12-04 EP EP24206281.8A patent/EP4506036A3/en active Pending
- 2015-12-04 SG SG11201704550XA patent/SG11201704550XA/en unknown
- 2015-12-04 NZ NZ732570A patent/NZ732570A/en not_active IP Right Cessation
-
2017
- 2017-06-04 IL IL252655A patent/IL252655B/en unknown
- 2017-06-05 US US15/614,108 patent/US11059891B2/en active Active
- 2017-06-05 PH PH12017501041A patent/PH12017501041A1/en unknown
-
2021
- 2021-05-27 US US17/332,853 patent/US12139538B2/en active Active
- 2021-11-04 IL IL287835A patent/IL287835A/en unknown
-
2022
- 2022-01-20 AU AU2022200381A patent/AU2022200381A1/en not_active Abandoned
- 2022-02-28 JP JP2022029515A patent/JP2022066290A/ja not_active Withdrawn
-
2024
- 2024-02-13 JP JP2024019513A patent/JP7864752B2/ja active Active
- 2024-10-08 US US18/909,536 patent/US20250059283A1/en active Pending
-
2026
- 2026-05-13 JP JP2026081108A patent/JP2026126417A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537925A5 (enExample) | ||
| JP2017537629A5 (enExample) | ||
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2022116230A (ja) | 免疫療法用改変細胞 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2022066290A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2015527070A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2016520074A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2019521645A5 (enExample) | ||
| IL275391B2 (en) | Antibodies binding ctla-4 and uses thereof | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| CN113603788A (zh) | 免疫调节剂 | |
| JP2017524367A5 (enExample) | ||
| JP2018500337A5 (enExample) | ||
| JP2022542559A5 (enExample) | ||
| CN111971059A (zh) | 使用过继细胞疗法和检查点抑制剂的组合疗法 | |
| WO2022147222A1 (en) | Antibodies to tnfr2 and uses thereof | |
| IL297916A (en) | Compositions and methods for tcr reprogramming using CD70-specific fusion proteins | |
| JP2023530083A (ja) | Ｈｌａ－ｇ及び別の抗原に対して結合特異性を有する二重特異性免疫細胞エンゲージャー | |
| WO2023285552A1 (en) | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |